Wow. Not to belabor the obvious, but here's the quote from

New Post Public Reply Private Reply Replies (4) Message Board
KenChowder ohm20 #112642
945
Wow. Not to belabor the obvious, but here's the quote from the link Ohm supplied. Frederick Hayden, of course, was the member of the DSMC for CD12 with links to Gilead. The quote below is from April 2020 -- a quote defending Remdesivir's results.

Quote:
Frederick Hayden, an infectious disease expert at the University of Virginia School of Medicine who helped the Chinese doctors conduct the study, disputed the characterization that the study had failed.

“That is not correct,” Hayden said in an interview, when asked whether the results showed remdesivir had flopped. “My interpretation of them is not consistent with that headline.”


Okay, that was April 2020. Hayden's pushing Remdesivir in a study he helmed.
In May 2020, based on a small reduction in hospital stay, but no improvement in mortality, Remdesivir got an EUA for severe patients.
In August 2020, authorized use of Remdesivir was expanded.
In October of the same year, Hayden is on DSMC that performs the interim analysis for Leronlimab. The Committee suggests no change in the trial.'

Remember that it was only because of a CHANGE in the primary endpoint that allowed Remdesivir to squeak through its trial. Hayden and company suggest no such change for Leron.

If they had suggested a change similar to the one that was used for Remdeceiver, Leron would have HIT ITS PRIMARY ENDPOINT.

Meanwhile, Gilead's drug has gone on to sell about $6 billion worth in 2020 and 2021. It has never demonstrated a reduction of mortality at all. Not in 14 days, not in 28 days.

I don't even care if I sound like a guy in a tin hat. I look at the above timetable and I get enraged that lives were thrown away so that Gilead could make $6 billion for not helping people, and a drug that could have saved many lives was tied to the starting block with a golden chain.

Foul is Fair, and Fair is Foul.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 22

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 64

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 24

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 104

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 78

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Updated Category News Views 131

Avicanna's 5th Medical Symposium on Cannabinoid Medicine On June 6, a well-anticipated medical symposium will be hosted by Avicanna Inc., a prominent biopharmaceutical company dedicated to the innovative exploration of cannabinoid-based medicine. This exciting event, taking place at the MaRS Discovery District, aims to bring together healthcare practitioners and...

Continue Reading
Gordian's Exciting New Initiative for Public Facility Planning

Updated Category News Views 277

Gordian's New Sourcewell Contract Gordian, a well-known provider of data-driven solutions for various phases of the building lifecycle, has recently secured a significant contract with Sourcewell. This partnership will broaden Gordian’s offerings to numerous government and educational organizations eager to enhance their facility planning capabilities. Facilitating...

Continue Reading
Paramount Global CFO Transition: A New Era Begins

Updated Category News Views 251

Paramount Global Announces Significant Leadership Change Paramount Global (NASDAQ: PARA) has made a noteworthy announcement regarding its executive leadership. Naveen Chopra, who has been serving as the Chief Financial Officer and Executive Vice President, will be departing from the company to explore new opportunities. The company's Board of Directors has stated that...

Continue Reading
Explore the Potential of Axsome, CRISPR, and Pfizer Stocks

Updated Category News Views 134

Back in 2023, the stock market was a mixed bag, with plenty of sectors showing serious signs of overvaluation. You had legends like Warren Buffett sitting on a mountain of cash, clearly indicating he saw overpriced stocks everywhere. When seasoned investors hit the brakes on buying due to high valuations, it’s like an alarm bell for everyone else—caution was in the...

Continue Reading
Boeing's Production Delays and Its Impact on Suppliers

Updated Category News Views 245

A Closer Look at Boeing's Production Setbacks Boeing Co has recently notified its suppliers about a significant change to a key production milestone for its 737 MAX aircraft. This adjustment, which extends the timeline by six months, has raised concerns within the aviation industry. Sources indicate that the new objective is to achieve an output of 42 jets per month by...

Continue Reading